Breckenridge is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $2.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Breckenridge's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Oct 2020; launched Mar 2026 | $2.7B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Breckenridge's share of it.